BioCentury on BioBusiness,
Analyst Picks & Changes
Analyst picks & changes
Published on
Monday, February 4, 2013
|
Company
|
Bank
|
Analyst
|
Coverage
|
Opinion
|
Wk
chg
|
2/1
cls
|
|
Celsion
Corp. (NASDAQ:CLSN)
|
Roth
Capital Partners
|
Joseph
Pantginis
|
Downgrade
|
Neutral
(from buy)
|
-83%
|
$1.32
|
|
Pantginis
also lowered his target to $1.70 from $10 after Celsion announced that its IV
ThermoDox failed in the Phase III HEAT trial to treat non-resectable
hepatocellular carcinoma (HCC) (see B18). He said his target is now
based solely on the Phase II study of ThermoDox in recurrent chest wall
breast cancer, and assigns a 10% chance of success in this indication. The
product is doxorubicin encapsulated in a heat-activated liposome.
|
|
Furiex
Pharmaceuticals Inc. (NASDAQ:FURX)
|
Canaccord
|
Randall
Stanicky
|
New
|
Buy
|
61%
|
$34.21
|
|
Stanicky
initiated coverage with a $45 target after FDA approved three Type II
diabetes products - Nesina alogliptin, Kazano alogliptin/metformin and Oseni
alogliptin/pioglitazone - from partner Takeda Pharmaceutical Co. Ltd.
(Tokyo:4502). Stanicky sees highly visible cash flow on royalties and
milestones for Furiex mainly from Nesina, which Takeda already markets in
Japan. Stanicky also see upcoming catalysts for Furiex's MuDelta, with Phase
III data to treat diarrhea-predominant irritable bowel syndrome (IBS-D)
expected early next year as well as "progressing" partnership
discussions. MuDelta is a locally acting mu opioid receptor agonist and delta
opioid receptor antagonist. Furiex co-developed alogliptin with Syrrx Inc.,
which Takeda acquired. Takeda said it plans to launch the alogliptin products
in the U.S. this summer. The products are under review in Europe.
|
230
words displayed of
917
words total.
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2013 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement and the BioCentury Terms of Use. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions at www.biocentury.com. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
|
Current Subscribers
If you are a current subscriber, log in below or in the upper right corner of this
page.
Log In
Subscription Option
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial 4 Weeks of Access
Get a 4-week free trial subscription to see the important articles you are missing.
Get 4 Weeks Free
Thank You
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
records.
close [ X ]